List of Excipients in Branded Drug SUGAMMADEX SODIUM

Generic Drugs Containing SUGAMMADEX SODIUM

Company	Ingredient	NDC	Excipient
Par Health USA LLC	sugammadex sodium	42023-830	HYDROCHLORIC ACID
Par Health USA LLC	sugammadex sodium	42023-830	SODIUM HYDROXIDE
STERISCIENCE SPECIALTIES PRIVATE LIMITED	sugammadex sodium	82449-241	HYDROCHLORIC ACID
STERISCIENCE SPECIALTIES PRIVATE LIMITED	sugammadex sodium	82449-241	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in SUGAMMADEX SODIUM?

# Of NDCs	Excipient
2	HYDROCHLORIC ACID
2	SODIUM HYDROXIDE

Sugammadex Sodium Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Sugammadex sodium is an intravenously administered, water-soluble modified gamma-cyclodextrin used to reverse neuromuscular blockade induced by rocuronium and vecuronium. Its commercial formulation is unusually simple: a high-concentration aqueous solution containing 100 mg/mL sugammadex, water for injection, and hydrochloric acid and/or sodium hydroxide for pH adjustment.[1]

The main excipient opportunity is therefore not a conventional formulation redesign. It is supply, quality, packaging, manufacturing efficiency, and differentiated delivery around a mature injectable product. The largest technical barrier remains the active pharmaceutical ingredient, which has a complex, highly substituted cyclodextrin structure and demanding impurity-control requirements.

What excipients are used in sugammadex sodium injection?

The U.S. Bridion formulation contains sugammadex sodium in water for injection. Hydrochloric acid and/or sodium hydroxide are used to adjust pH.[1]

Component	Function	Commercial significance
Sugammadex sodium	Active ingredient; modified gamma-cyclodextrin	Primary cost and manufacturing driver
Water for injection	Sterile aqueous vehicle	Requires validated pharmaceutical water and aseptic controls
Hydrochloric acid	pH adjustment	Commodity excipient with sterile-processing requirements
Sodium hydroxide	pH adjustment	Commodity excipient with sterile-processing requirements
Container closure system	Product protection and sterility maintenance	Important for extractables, leachables, and stability

The marketed solution has a pH generally controlled near neutrality. The formulation avoids preservatives, surfactants, co-solvents, tonicity agents, and antimicrobial excipients. This reduces formulation complexity and limits opportunities to substitute excipients without changing the product's risk profile.

Why is the excipient list short?

Sugammadex sodium is highly water soluble and is administered in a hospital setting by intravenous injection. A simple aqueous formulation reduces risks associated with precipitation, local irritation, incompatibility, and excipient-mediated toxicity.

The formulation also avoids unnecessary excipients in a product used for rapid perioperative administration. Any new excipient would require a clear technical justification because the reference product already provides a stable, ready-to-use solution.

What formulation properties control sugammadex sodium product quality?

The critical quality attributes are driven more by the active ingredient and sterile solution than by excipient innovation.

Key parameters include:

• Assay and related substances
• Degree and pattern of sulfobutyl ether substitution
• Residual solvents and elemental impurities
• pH
• Osmolality
• Color and clarity
• Visible and subvisible particles
• Sterility and bacterial endotoxins
• Extractables and leachables
• Container-closure integrity
• Stability after vial opening or dilution, where applicable

Sugammadex is a polyanionic cyclodextrin derivative. Its substitution profile affects molecular weight distribution, charge density, complexation behavior, and impurity characterization. Regulators are likely to focus on control of substitution-related variants rather than accepting broad similarity based only on assay and chromatographic purity.

Which excipient strategies are commercially viable?

1. Direct excipient substitution

This is the weakest strategy. The reference formulation uses only water for injection and pH adjusters. Replacing hydrochloric acid or sodium hydroxide with another acid-base system could affect pH, osmolality, stability, compatibility, and regulatory comparability.

Potential alternatives include:

• Phosphate buffers
• Citrate buffers
• Acetate buffers
• Other mineral acids or bases

These options may be technically feasible but have limited commercial value. A buffer can add ionic strength, alter complexation behavior, create precipitation risk, and complicate equivalence to the reference product.

2. Ready-to-use sterile formulation

A more practical opportunity is a presentation that reduces hospital preparation steps. Potential formats include:

• Single-dose vials
• Ready-to-use prefilled syringes
• Small-volume bags
• Dual-chamber systems
• Unit-dose emergency kits

A prefilled syringe could reduce dose-preparation time and medication-error risk. The commercial case depends on compatibility with existing anesthesia workflows, syringe stability, terminal sterilization constraints, and the ability to demonstrate container-closure integrity.

3. Low-volume, high-concentration presentation

The reference concentration is already 100 mg/mL, so further concentration may provide limited benefit. The key value is dose flexibility. Sugammadex is commonly administered at 2 mg/kg, 4 mg/kg, or 16 mg/kg depending on the depth of neuromuscular blockade.[1]

A product designed around standard adult dosing could reduce vial waste. The opportunity is strongest where hospitals use large numbers of 2 mL and 5 mL vials and where dose rounding produces residual drug waste.

4. Packaging and device differentiation

Packaging may provide a stronger commercial position than excipient substitution. Relevant options include:

• Low-sorption polymer syringes
• Latex-free closures
• Improved vial labeling
• Barcode-enabled unit doses
• Dose-specific kits
• Tamper-evident emergency packaging
• Packaging optimized for refrigerated or controlled room-temperature distribution

The packaging must preserve solution stability and avoid adsorption or leaching. Cyclodextrin-based products can interact with packaging components, particularly where high concentrations and long storage periods are involved.

How does sugammadex sodium compare with competing neuromuscular reversal products?

Sugammadex competes primarily with neostigmine-based reversal, although the products have different mechanisms and excipient profiles.

Attribute	Sugammadex sodium	Neostigmine methylsulfate
Drug class	Modified gamma-cyclodextrin	Acetylcholinesterase inhibitor
Mechanism	Encapsulates rocuronium or vecuronium	Increases acetylcholine at the neuromuscular junction
Administration	IV injection	IV injection
Anticholinergic co-medication	Generally not required for mechanism	Commonly paired with glycopyrrolate or atropine
Formulation opportunity	Simple aqueous solution	Combination workflow and co-administration
Generic pathway	ANDA for a small-molecule drug	ANDA for a small-molecule drug
Main differentiation	Speed, predictability, and workflow	Lower acquisition cost

Sugammadex has a higher active pharmaceutical ingredient cost than neostigmine, but hospitals may value faster reversal, reduced recovery-room delays, and fewer medication steps. Formulation-based commercial differentiation should focus on dose management and administration convenience rather than new excipient chemistry.

What manufacturing barriers affect sugammadex sodium?

The active ingredient is the principal manufacturing barrier.

Sugammadex is produced by modifying gamma-cyclodextrin through a multistep chemical process. The process must control:

• Cyclodextrin starting-material quality
• Selective functionalization
• Degree of substitution
• Positional isomers and substitution patterns
• Residual reagents and solvents
• Inorganic salts
• Color bodies and degradation products
• Batch-to-batch molecular-weight distribution

The product is not a conventional low-molecular-weight API with a single, easily characterized molecular entity. Its structural complexity creates a higher analytical burden. Process know-how, validated impurity methods, and reliable high-purity starting materials can create meaningful barriers even after core composition patents expire.

For excipient suppliers, the opportunity is more credible in high-purity sterile-grade water systems, pH-adjustment materials, container components, and analytical services than in novel functional excipients.

What patents protect sugammadex sodium?

The original intellectual-property estate centered on modified cyclodextrins, including sugammadex-related compositions and their use in reversing neuromuscular blockade. Merck's early patent filings covered modified cyclodextrin compounds, pharmaceutical compositions, and reversal of steroidal neuromuscular blockers.[2]

Core composition protection in the United States has expired or reached the end of its ordinary patent term, enabling generic development through the ANDA pathway. The commercial risk now shifts toward:

• Later-filed process patents
• Crystalline or solid-state forms, where applicable
• Purification methods
• Synthetic intermediates
• Specific formulations
• Container systems
• Method-of-use patents
• Trade secrets covering substitution control and impurity removal

A generic applicant must evaluate the current Orange Book listing, patent-term adjustments, pediatric extensions, and any listed method-of-use patents before filing. FDA's Orange Book identifies approved drug products, therapeutic equivalence evaluations, patent information, and regulatory exclusivity.[3]

Are formulation patents likely to block generic sugammadex?

Formulation patents are less likely to be the primary barrier because the reference product has a minimal excipient composition. A patent directed broadly to sugammadex in water for injection could face validity and obviousness challenges if the disclosure is narrow or predictable.

More defensible later patents could cover:

• Specific pH ranges combined with stability limits
• Low-particulate formulations
• Defined substitution distributions
• Particular sterilization processes
• Prefilled syringes or specialized containers
• Dilution or administration protocols
• Long-term stability under defined storage conditions

The practical value of such patents depends on whether a generic can design around them while maintaining pharmaceutical equivalence.

When did sugammadex lose market exclusivity?

FDA approved Bridion in December 2015.[1] The product's five-year new chemical entity exclusivity period generally ran until late 2020, subject to the FDA approval date and any applicable pediatric extension. Sugammadex is a small-molecule drug, so it is subject to the generic ANDA pathway rather than the biosimilar pathway.

The commercial exclusivity timeline is separate from patent expiry. Patent protection may continue after regulatory exclusivity ends, while a generic may challenge listed patents through Paragraph IV certification.

Milestone	Approximate timing
U.S. approval of Bridion	December 2015
Five-year NCE exclusivity	Approximately through December 2020
Generic pathway	ANDA
Biosimilar pathway	Not applicable
Core composition-patent risk	Largely mature or expired
Current competitive focus	Generic supply, API quality, manufacturing, and hospital contracting

Which companies are challenging or competing with Bridion?

Competition includes generic manufacturers and the established neostigmine market. Generic sugammadex suppliers can compete through:

• FDA-approved injectable products
• Lower acquisition cost
• Multi-dose purchasing contracts
• Reliable API sourcing
• Fewer backorders
• Compatible vial sizes
• Pharmacy-friendly packaging
• Hospital group purchasing organization access

The most important competitive variable is likely supply reliability. A generic with a technically equivalent product but unstable API sourcing may be less attractive than a higher-priced supplier with dependable availability.

Because sugammadex is administered in operating rooms, hospital formulary adoption and anesthesia department preference can matter as much as pharmacy acquisition price. A supplier that offers dose-specific packaging, barcode integration, and predictable inventory may capture value without changing the formulation.

What FDA regulatory issues apply to sugammadex sodium generics?

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements. For an injectable solution, the applicant generally benefits from the absence of absorption-related bioequivalence issues when the product is qualitatively and quantitatively equivalent and delivered by the same route.[4]

The major regulatory issues are likely to include:

• Same active ingredient and strength
• Same dosage form and route
• Comparable inactive ingredients
• pH and osmolality control
• Sterility assurance
• Endotoxin limits
• Particulate control
• Container-closure integrity
• Extractables and leachables
• API structural and impurity characterization
• Manufacturing-process validation

A material change in excipient composition can increase the need for comparative stability, compatibility, and safety justification. A simple formulation matching the reference product is usually the lower-risk development strategy.

What generic launch scenarios exist for sugammadex sodium?

Price-led launch

A conventional generic can enter with a lower price and compete for hospital contracts. This is the most direct strategy but may produce rapid price erosion if several suppliers enter.

Supply-led launch

A manufacturer can position around high service levels, dual API sourcing, and consistent fill-finish capacity. This strategy is relevant because injectable shortages and supply interruptions can influence hospital purchasing decisions.

Workflow-led launch

A ready-to-use syringe or dose-optimized presentation can command a premium if it reduces preparation time, waste, or medication errors. The product would require a clear human-factors and packaging rationale.

Regional licensing

A regional pharmaceutical company could license an approved or near-approval product from an API or injectable manufacturer. The most attractive partners would have:

• Sterile injectable manufacturing
• Hospital sales infrastructure
• Existing anesthesia products
• Regulatory coverage in multiple jurisdictions
• Access to high-purity sugammadex API

How large is the commercial opportunity for excipient suppliers?

The excipient revenue opportunity per dose is limited because the finished formulation contains primarily water for injection and pH adjusters. The higher-value opportunities are adjacent:

1. Pharmaceutical-grade water and sterile utilities
2. High-purity hydrochloric acid and sodium hydroxide
3. Low-extractables vial and syringe components
4. Analytical methods for cyclodextrin-related impurities
5. Contract fill-finish and aseptic manufacturing
6. Stability and packaging qualification
7. Dose-optimization and ready-to-use delivery systems

Revenue exposure is therefore concentrated in the active ingredient, fill-finish operation, and hospital distribution channel. Excipient substitution alone is unlikely to create a durable premium unless it enables a differentiated presentation or solves a demonstrated stability, compatibility, or workflow problem.

Key Takeaways

• Sugammadex sodium injection uses a minimal formulation: active ingredient, water for injection, and pH adjusters.
• Novel excipient substitution has limited commercial value and could increase regulatory and comparability risk.
• The strongest opportunities are ready-to-use formats, dose-specific packaging, sterile fill-finish, and supply reliability.
• Sugammadex is a small-molecule drug subject to the ANDA pathway; biosimilar competition does not apply.
• Core composition-patent barriers are mature, while process, impurity-control, formulation, packaging, and method-of-use patents remain relevant.
• The principal manufacturing barrier is production and characterization of the modified cyclodextrin API.
• Hospital contracting, anesthesia workflow, inventory reliability, and vial waste are more important commercial levers than excipient innovation.

FAQs About Sugammadex Sodium Formulation and Commercial Strategy

Can sugammadex sodium be formulated without sodium hydroxide or hydrochloric acid?

Yes, other pH-adjusting systems may be technically possible, but changing the formulation can affect stability, osmolality, compatibility, and regulatory comparability. The reference formulation uses hydrochloric acid and/or sodium hydroxide for pH adjustment.[1]

Is sugammadex sodium a cyclodextrin excipient?

No. Sugammadex sodium is the active pharmaceutical ingredient. It is a modified gamma-cyclodextrin designed to encapsulate rocuronium and vecuronium.

Does sugammadex sodium require a preservative?

The reference product is a preservative-free sterile injectable solution. A preservative would add safety, compatibility, and regulatory complexity without an obvious clinical benefit for a single-dose intravenous product.

Are prefilled syringes commercially attractive for sugammadex?

They can be attractive where they reduce preparation time, dose errors, and vial waste. The business case depends on syringe stability, device compatibility, manufacturing cost, and hospital purchasing behavior.

What is the most defensible IP for a new sugammadex product?

Later-filed patents covering defined impurity profiles, manufacturing processes, substitution control, stable formulations, packaging systems, or differentiated administration formats are generally more defensible than broad claims covering sugammadex in a simple aqueous solution.

References

1. U.S. Food and Drug Administration. (2015). Bridion (sugammadex) injection, prescribing information.
2. Merck & Co., Inc. (2004). Modified gamma-cyclodextrins and their use as neuromuscular blockade reversal agents. U.S. Patent No. 6,670,340.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
4. U.S. Food and Drug Administration. (2014). Bioequivalence studies for drug products submitted under an ANDA: Guidance for industry.